CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis

Annals of Clinical and Laboratory Science

Volumn 37, Issue 2, 2007, Pages 148-151

  Zhang, Ping L ^a,b   Pennington, Jared R ^a   Prichard, Jeffery W ^a   Blasick, Thomas M ^b   Brown, Adam M ^a   Potdar, Santosh ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b WEIS CENTER FOR RESEARCH   (United States)

Author keywords

Alemtuzumab; Campath 1H; CD52; Eosinophilia; Rhinosinusitis; Tissue microarray

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN;

ADULT; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMAGING SYSTEM; KIDNEY GRAFT; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MALE; MONOCYTE; MORPHOLOGY; PRIORITY JOURNAL; RHINOSINUSITIS; TISSUE MICROARRAY; TISSUE SECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; EOSINOPHILS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; RHINITIS; SINUSITIS; TISSUE ARRAY ANALYSIS;

EID: 34248145517     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jones N. Allergic rhinitis: etiology, predisposing and risk factors. Rhinology 2004;42:49-56.
2. Hansen I, Klimek L, Mosges R, Hormann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opinion Allergy Clin Immunol 2004;4: 159-163.
3. Taylor-Clark T, John F. Histamine-mediated mechanisms in the human nasal airway. Curr Opinion Pharma-col 2005;5:214-220.
4. Meltzer EO, Szwarcberg J, Pill MW, Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. J Managed Care Pharm 2004;10:310-317.
5. Morgan MM, Khan DA, Nathan RA. Treatment of allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacol 2005;39: 2056-2064.
6. Van Cauwenberge P, Van Hoecke H. Management of allergic rhinitis. B-ENT. 2005;Suppl 1:45-62.
7. Waldmann H. A personal hisrory of rhe Camparh-1H anribody. Med Oncol 2002;19(Suppl):S3-S9.
8. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem 1995;270:6088-6099.
9. Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88:4684-4693.
10. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003: 101:1422-1429.
11. Buggins AGS, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002:100:1715.
12. Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004;136:754.
13. Zhang PL, Malek SK, Prichard JW, Lin F, Tahya TM, Schwartzman MS, Latsha RP, Norfolk ER, Blasick TM, Lun M, Brown RE, Hartle JE, Potdar S. Acute renal rejection predominated by monocytes is a severe form of rejection in human recipients with or without Campath-1H (Alemtuzumab) induction therapy. Am J Transplant 2005;5:604.
14. Krauth MT, Agis H, Aichberger KJ, Simonitsch-Klupp I, Mullauer L, Mayerhofer M, Bohm A, Horny HP, Valen P. Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. Human Pathol 2006;37:439-447.
15. Veinot JP, Prichett-Pejic W, Song J. CD117-positive cells and mast cells in adult human cardiac valves: observations and implications for the creation of bioengineered grafts. Cardiovasc Pathol 2006;15:36-40.